Test Drive Our New Site! We have some improvements in the works that we're excited for you to experience. Click here to try our new, faster, mobile friendly beta site. We will be maintaining our current version of the site thru the end of 2024, so you can switch back as our improvements continue.
Legislation Quick Search
04/23/2024 06:46 PM
Pennsylvania House of Representatives
https://www.legis.state.pa.us/cfdocs/Legis/CSM/showMemoPublic.cfm?chamber=H&SPick=20150&cosponId=15897
Share:
Home / House Co-Sponsorship Memoranda

House Co-Sponsorship Memoranda

Subscribe to PaLegis Notifications
NEW!

Subscribe to receive notifications of new Co-Sponsorship Memos circulated

By Member | By Date | Keyword Search


House of Representatives
Session of 2015 - 2016 Regular Session

MEMORANDUM

Posted: December 12, 2014 03:37 PM
From: Representative Matthew E. Baker
To: All House members
Subject: Oral Chemo Parity Legislation
 
In the near future, I will be re-introducing the Oral Chemo Parity legislation (former HB 2471) that will provide for equal access to chemotherapy treatments.

Over the years, cancer treatment methods have been changing. Traditional anti-cancer medications were primarily administered intravenously, attacking both cancerous and healthy cells alike. Conversely, orally administered anti-cancer medications have been developed more recently to target only cancer cells, having fewer side effects. Additionally, oral anti-cancer medications have shown to be far more effective for some forms of cancer.

Intravenous anti-cancer medications are typically covered under a health plan's medical benefit, often requiring patients to pay a minimal fixed co-payment. Orally-administered anticancer medications, however, are covered under a health plan's pharmacy benefit. Under the pharmacy benefit, oral anti-cancer medications are classified in the highest tier of a health plan’s cost-sharing system, requiring patients to pay a percentage of the total cost of the drug, generally between 25-30%. This creates an enormous financial barrier for patients to access orally administered drugs prescribed by their cancer physician for treatment.

Increases in out-of-pocket costs of anti-cancer medications can lead to a decrease in adherence to treatment, further risking patient health and making treatment longer, more expensive and less effective.

My legislation will prohibit insurance policies from placing oral anti-cancer medications on a specialty tier or charging a coinsurance payment for the medication, helping more patients afford a more convenient form of cancer treatment. As of August 2014, 34 states have enacted oral chemotherapy access laws.

I hope you will join in co-sponsoring this important legislation that will increase access for cancer patients. This legislation is supported by the Leukemia & Lymphoma Society. Thank you for your interest and support.

PREVIOUS COSPONSORS: BENNINGHOFF, CAUSER, HEFFLEY, MURT,
KNOWLES, V. BROWN, DAVIS, BOBACK, LONGIETTI, McCARTER, KOTIK,
D. COSTA, MILLARD, KILLION, WATSON, EVERETT, CUTLER, BARRAR,
GIBBONS, HARHART, DiGIROLAMO, ROCK, COHEN, DONATUCCI,
SCHLOSSBERG, KAUFFMAN, PICKETT, MATZIE, CLYMER, PETRI,
GINGRICH, SWANGER, BROOKS, GROVE, BIZZARRO, MILNE, DeLUCA,
ENGLISH AND SAMUELSON,



Introduced as HB60